Nonmyeloablative Alternative Donor Transplantation for Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR
Giancarlo Fatobene(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Mary Eapen(Medical College of Wisconsin), Silvia Montoto(Queen Mary University of London), Mehdi Hamadani(Medical College of Wisconsin), Hanadi R. El Ayoubi, Mohamed A. Kharfan‐Dabaja(Jacksonville College), Luca Castagna(Humanitas University), Stephen Robinson(Intel (United States)), Fernanda Volt(Université Paris Cité), Claudio G. Brunstein(Hotel Dieu Hospital), Asad Bashey, Chantal Kenzey(European Organisation for Rare Diseases), Éliane Gluckman(Assistance Publique – Hôpitaux de Paris), Ibrahim Yakoub‐Agha(Inserm), Hervé Finel, José M. Moraleda(Centro Regional de Hemodonación), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Annalisa Ruggeri(Inserm), Miguel‐Angel Perales(Memorial Sloan Kettering Cancer Center), Alida Dominietto(Ospedale Policlinico San Martino), Andrew St. Martin(Johns Hopkins Hospital), Yves Chalandon(University of Geneva), Hélène Labussière‐Wallet(Hospices Civils de Lyon), Rocco Pastano(European Institute of Oncology), Ariane Boumendil(Inserm), Mei-Jie Zhang(Medical College of Wisconsin), Vanderson Rocha(Fundação Pró-Sangue Hemocentro de São Paulo)
Cited by 44
Related Papers
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
|Nature|2010|1.3k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation
|Blood|2014|880
Intestinal Blautia Is Associated with Reduced Death from Graft-versus-Host Disease
|Biology of Blood and Marrow Transplantation|2015|762